Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,158 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atherosclerosis, Coronary Clear all
Recruiting Not applicable Interventional

Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease

NCT05788666
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
GeriKit Mobile Application
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
75 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 15, 2026, 5:53 AM EDT
Terminated Phase 4 Interventional Results available

Coronary Artery Revascularization in Diabetes

NCT00326196
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG)
Device · Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 15, 2026, 5:53 AM EDT
Terminated No phase listed Observational Results available

The PEARL 8.0 Post-Approval Study

NCT01845103
View directory record Official record
Conditions
Class IV Angina
Interventions
Not listed
Lead sponsor
Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 15, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI)

NCT00353795
View directory record Official record
Conditions
Coronary Arteriosclerosis, Arteriosclerosis, Coronary, Atherosclerosis, Coronary, Coronary Artery Disease, Coronary Atherosclerosis
Interventions
MR Imaging of the Coronary Arteries
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 15, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

NCT02265796
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 15, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

NCT01435031
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Chronic Total Occlusion (CTO)
Interventions
CTO Treatment Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 15, 2026, 5:53 AM EDT
Completed Phase 4 Interventional Results available

Investigation of the Athero-Protective Effects of Clopidogrel

NCT01283282
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 15, 2026, 5:53 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The DISCOVER INOCA Prospective Multi-center Registry

NCT05288361
View directory record Official record
Conditions
Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Interventions
Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 15, 2026, 5:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating a Web-Based Educational Program for Adults at Risk for Coronary Heart Disease (The Heart to Heart Feasibility Study)

NCT00494052
View directory record Official record
Conditions
Coronary Disease, Cardiovascular Diseases
Interventions
Heart to Heart (Web-Based Decision Aid), Physician Education Session
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 79 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 15, 2026, 5:53 AM EDT
Terminated Phase 3 Interventional

A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI

NCT01848106
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
pegnivacogin/anivamersen, Bivalirudin
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 15, 2026, 5:53 AM EDT
Recruiting Not applicable Interventional

Determinants of Cardiorespiratory Fitness and Effects of HIIT in Patients With ANOCA Obstructive Coronary Artery Disease(ANOCA)

NCT07182955
View directory record Official record
Conditions
MINOCA, Shortness of Breath, Atherosclerotic Heart Disease of Native Coronary Artery
Interventions
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 15, 2026, 5:53 AM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of the Blood Vessels of the Heart

NCT00001638
View directory record Official record
Conditions
Heart Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
2,916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 15, 2026, 5:53 AM EDT
Completed No phase listed Observational

Diagnosis and Treatment of ACS in the ED: The Impact of Rapid Bedside cTnI Testing on Outcomes

NCT00222352
View directory record Official record
Conditions
Angina, Unstable
Interventions
Point of Care cTnL testing
Diagnostic Test
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Stanford, California • Royal Oak, Michigan • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 15, 2026, 5:53 AM EDT
Active, not recruiting Phase 4 Interventional

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747
View directory record Official record
Conditions
Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions
Evolocumab, Routine Lipid Management
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
6,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 15, 2026, 5:53 AM EDT
Completed Phase 4 Interventional Results available

Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

NCT02287909
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 15, 2026, 5:53 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study to Validate Simple Acute Coronary Syndrome Score

NCT00947804
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
St. Joseph's Hospital, Florida
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 15, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery

NCT00413244
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AndroGel 5 Grams, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 15, 2026, 5:53 AM EDT
Completed No phase listed Observational

An Observational Study of Cholesterol in Coronary Arteries

NCT00831116
View directory record Official record
Conditions
Myocardial Infarction, Angina, Coronary Artery Disease, Myocardial Ischemia
Interventions
Intravascular Near Infrared Spectroscopy
Device
Lead sponsor
Infraredx
Industry
Eligibility
18 Years and older
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
22
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 15, 2026, 5:53 AM EDT
Terminated Not applicable Interventional

CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow

NCT01268319
View directory record Official record
Conditions
Coronary Atherosclerosis, Myocardial Infarction, Coronary Plaque Embolization
Interventions
Embolic Protection Device (EPD), Intracoronary Spectroscopy and Ultrasonic Evaluation, Angioplasty and Stent Implant
Device
Lead sponsor
Infraredx
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 15, 2026, 5:53 AM EDT
Completed Not applicable Interventional

CPR Training in 7th Grade Students

NCT00570609
View directory record Official record
Conditions
Coronary Atherosclerosis, Prevention of Heart Disease
Interventions
CPR Anytime education
Other
Lead sponsor
Marna Rayl Greenberg
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Oct 15, 2026, 5:53 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 15, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

NCT01245634
View directory record Official record
Conditions
Coronary Heart Disease, Graft Occlusion, Vascular
Interventions
Placebo, RO4905417
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 85 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Huntsville, Alabama • Tucson, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 15, 2026, 5:53 AM EDT
Completed No phase listed Observational

Rubidium-82 Position Emission Computed Tomography (PET) Versus Gated, Rest / Stress Technetium 99-m SPECT

NCT01179230
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia, Heart Disease
Interventions
SPECT imaging, PET imaging
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
50 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Huntsville, Alabama • Hartford, Connecticut • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 15, 2026, 5:53 AM EDT
Suspended Not applicable Interventional

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

NCT06071702
View directory record Official record
Conditions
Coronary Stenosis, Coronary Artery Disease
Interventions
IoNIR Ridaforolimus-Eluting Coronary Stent System
Device
Lead sponsor
Medinol Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 5:53 AM EDT